Zweig DiMenna Associates LLC purchased a new position in Chemours Company (The) (NYSE:CC) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 4,200 shares of the specialty chemicals company’s stock, valued at approximately $213,000.

A number of other hedge funds have also modified their holdings of CC. FMR LLC boosted its holdings in shares of Chemours Company (The) by 6.1% during the 2nd quarter. FMR LLC now owns 15,830,411 shares of the specialty chemicals company’s stock valued at $600,289,000 after purchasing an additional 905,038 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Chemours Company (The) by 10.3% during the 2nd quarter. Renaissance Technologies LLC now owns 3,342,200 shares of the specialty chemicals company’s stock valued at $126,736,000 after purchasing an additional 310,800 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Chemours Company (The) by 10.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,966,582 shares of the specialty chemicals company’s stock valued at $74,573,000 after purchasing an additional 186,228 shares during the last quarter. TIAA CREF Investment Management LLC boosted its holdings in shares of Chemours Company (The) by 126.5% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,789,112 shares of the specialty chemicals company’s stock valued at $67,843,000 after purchasing an additional 999,380 shares during the last quarter. Finally, AJO LP bought a new position in shares of Chemours Company (The) during the 2nd quarter valued at about $49,809,000. Institutional investors and hedge funds own 72.90% of the company’s stock.

In other Chemours Company (The) news, insider E Bryan Snell sold 11,878 shares of the firm’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $53.25, for a total value of $632,503.50. Following the completion of the sale, the insider now owns 63,063 shares of the company’s stock, valued at $3,358,104.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP David C. Shelton sold 13,337 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $48.48, for a total transaction of $646,577.76. The disclosure for this sale can be found here. In the last ninety days, insiders sold 76,520 shares of company stock valued at $4,008,293. 1.14% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: This report was posted by Daily Political and is owned by of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/11/14/4200-shares-in-chemours-company-the-cc-purchased-by-zweig-dimenna-associates-llc.html.

Several research analysts have commented on CC shares. Citigroup Inc. increased their price objective on shares of Chemours Company (The) from $45.00 to $59.00 and gave the company a “buy” rating in a report on Friday, August 4th. Jefferies Group LLC increased their price objective on shares of Chemours Company (The) to $60.00 and gave the company a “buy” rating in a report on Thursday, August 3rd. Argus reissued a “buy” rating and set a $55.00 price objective (up previously from $50.00) on shares of Chemours Company (The) in a report on Thursday, August 10th. BidaskClub raised shares of Chemours Company (The) from a “hold” rating to a “buy” rating in a report on Thursday, August 24th. Finally, Zacks Investment Research raised shares of Chemours Company (The) from a “hold” rating to a “buy” rating and set a $57.00 price objective for the company in a report on Thursday, November 9th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. Chemours Company (The) presently has an average rating of “Buy” and a consensus target price of $53.89.

Chemours Company (NYSE CC) opened at $51.46 on Tuesday. The company has a debt-to-equity ratio of 5.07, a current ratio of 2.19 and a quick ratio of 1.63. Chemours Company has a 1-year low of $20.38 and a 1-year high of $58.08. The company has a market cap of $9,271.12, a PE ratio of 17.75, a P/E/G ratio of 0.89 and a beta of 3.59.

Chemours Company (The) (NYSE:CC) last announced its quarterly earnings results on Thursday, November 2nd. The specialty chemicals company reported $1.12 EPS for the quarter, beating the Zacks’ consensus estimate of $1.01 by $0.11. Chemours Company (The) had a net margin of 4.86% and a return on equity of 116.80%. The firm had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter last year, the firm earned $0.61 EPS. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. research analysts expect that Chemours Company will post 3.65 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Monday, November 20th will be issued a $0.03 dividend. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.23%. The ex-dividend date of this dividend is Friday, November 17th. Chemours Company (The)’s payout ratio is 8.28%.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.